Research programme: siRNA hepatitis therapeutics - Alnylam Pharmaceuticals
Alternative Names: Sirna-034; Sirna-AV34Latest Information Update: 16 May 2014
At a glance
- Originator Sirna Therapeutics
- Class Small interfering RNA
- Mechanism of Action RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B; Hepatitis C
Most Recent Events
- 06 Mar 2014 Alnylam Pharmaceuticals acquires Sirna Therapeutics
- 30 Dec 2006 Sirna Therapeutics has been acquired by Merck and Co
- 22 Jun 2005 Preclinical data presented at the 8th Annual Meeting of the American Society of Gene Therapy (ASGT-2005) have been added to the Viral infections pharmacodynamics section